In the CRUK Cambridge Centre, we offer both treatment for today’s patients and research into improving treatment and prevention of lung cancer in the future.
At Addenbrooke’s and Papworth we offer today’s patients a full diagnostic and treatment service which helps over 500 patients every year. The interests of the patient are always the top priority. We offer patients the best routine care. Whenever possible, we also offer patients the opportunity to take part in clinical research.
Tailored treatment for each patient
The latest techniques are used both in routine practice and in research protocols to provide a very accurate diagnosis, including the exact type and extent of disease and the molecular characteristics of the disease. Specialised techniques include endobronchial ultrasound biopsy, MRI assessment of lung nodules and molecular characterisation within the Cancer Research UK Stratified Medicine Initiative. Together, these techniques allow the team to tailor treatment to the individual. Where possible, surgery is offered at Papworth to remove fully the cancer. Where this is not possible, the patient will be offered appropriate medical treatment at Addenbrooke’s which may include radiotherapy or drug treatment.
Creating a centre of excellence
Cambridge is the regional referral centre for lung cancer. Addenbrooke's Hospital has a substantial patient base with over 500 new referrals annually, research bronchoscopy clinics, and a highly performing clinical trials team including early phase clinical trials expertise. Papworth Hospital will soon relocate to the Cambridge Biomedical Campus to form the largest cardio-thoracic centre in Europe.
Minimally invasive strategies for identification of high-risk patients
Addenbrooke's Hospital carries out over 150 research bronchoscopies every year and is the second highest recruiter to LungSearch (a trial testing ways of detecting lung cancer at an early stage in people whose lungs are not working normally). Research is focused on developing minimally invasive strategies for identifying high-risk patients, including sampling upper airway mucosa, genomics of plasma and/or sputum DNA, novel imaging techniques, bronchoscopic studies, and detailed clinical and epidemiological surveys.
An early phase trial looking at the effect of combining two molecular targeted drugs for patients with advanced cancers
The purpose of this trial is to study the combination of vandetanib and selumetinib, novel agents which target the growth factors EGFR/VEGF and MEK, respectively. Cancers are often driven by multiple molecular aberrations, so it is important to find out whether inhibition of multiple oncogenic pathways might lead to better clinical outcomes. The first part of this phase I trial will include patients with any solid tumour and the second part of the trial will include only patients with non small-cell lung cancer. The trial aims to find out if the two drugs can be given together safely, the maximum dose that can be given, potential side effects and what happens to the drugs inside the body.
Current open trials in Cambridge
The table below lists current open trials for lung cancer coordinated by the Cambridge Cancer Trials Centre (last updated January 2016).
|Trial name||Trial description||Contact|
|CRUK Stratified Medicine Pilot study||The Cancer Research UK Stratified Medicine Programme: Pilot Study||Prof Peter Collins|
|Isotoxic IMRT Study||Isotoxic Intensity Modulated Radiotherapy (IMRT) in stage III non small cell lung cancer (NSCLC) - A Feasibility Study||Dr Susan Harden|
|LUCID||LUng cancer CIrculating tumour Dna Study||Dr Susan Harden|
|National Lung Matrix Trial||Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer||Dr David Gilligan|
|NCRN - 3003: TRAP - study in subjects with MPM, PM or NSCLC||Phase 1 Study in Subjects with Tumors Requiring Arginine to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study)||Dr Simon Pacey|
If you would like further information about how to take part in any of the clinical trials listed here that are open to recruitment, please talk to your cancer specialist as patients usually need to be referred by their doctor.
Cambridge Cancer Trials Centre contact for thoracic cancer trials: Dr Susan Harden